Replies to post #111758 on Biotech Values

[oc631]

The deal structures will embrace "shared risk". The days when biotech enjoyed major upfront payments for pharma companies to access their technologies are over

Disagree on this generalization. There will always be exciting, new innovations that large pharma will pay upfront for.